Sample Size Esti­mate in BE Studies [Power / Sample Size]

posted by Sereng  – USA, 2022-05-12 19:22 (1103 d 03:38 ago) – Posting: # 22976
Views: 3,067

Dear colleagues, in BE studies that must be conducted as parallel group design (e.g., depot formulations with sampling for 2 to 3 months), (i) is the sample size generally the same when compared to crossover design studies? and (ii) how do you estimate sample size when the known CV of the reference drug is excessive and much higher (e.g., double or triple) than the estimated CV of the Test drug? Regards

Biostatistically Challenged CEO

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,681 registered users;
67 visitors (0 registered, 67 guests [including 19 identified bots]).
Forum time: 23:01 CEST (Europe/Vienna)

Mediocrity knows nothing higher than itself,
but talent instantly recognizes genius.    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5